High-Load AG10 Tablet Formulations for Stable Dissolution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical formulations of AG10 suffer from instability and inconsistent pharmacokinetic data, particularly when high loads of AG10 are required, leading to issues such as tablet erosion and reduced dissolution rates during extended storage.
Innovation Solution
The use of high-grade microcrystalline cellulose with spherical morphology and porous structure or needle-like particle shape, combined with specific ratios of fillers, disintegrants, and lubricants, to create tablet formulations that maintain stability and consistent pharmacokinetic profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high loads of AG10 are used in tablet formulations, then the therapeutic efficacy is improved, but the stability of the formulation deteriorates leading to tablet erosion and reduced dissolution rates during extended storage
Solution Approach 1:
The patent applies parameter changes by modifying the physical and chemical parameters of the formulation components. Specifically, it uses high-grade microcrystalline cellulose with controlled particle size (10-50 μm) and specific surface area (1.5-3.0 m²/g), along with optimizing the ratio of excipients (microcrystalline cellulose 30-70%, colloidal silicon dioxide 1-10%, magnesium stearate 1-5%). These parameter optimizations enable the formulation to maintain stability even with high AG10 loads (60-85% w/w), resolving the contradiction between drug load and formulation stability.
2Quantity of substance
If high loads of AG10 are used in tablet formulations, then the therapeutic efficacy is improved, but the dissolution rate deteriorates during extended storage
Solution Approach 1:
The patent optimizes physical parameters of the excipients to maintain dissolution rate. High-grade microcrystalline cellulose with specific particle size (10-50 μm) and surface area (1.5-3.0 m²/g) provides adequate porosity and surface area for drug dissolution. The controlled pore volume (0.3-0.6 mL/g) ensures proper water penetration and drug release, allowing high AG10 loads (60-85% w/w) to maintain consistent dissolution rates even after extended storage.
Solution Approach 2:
The patent creates a composite tablet formulation combining AG10 with a specific ratio of excipients: microcrystalline cellulose (30-70%), colloidal silicon dioxide (1-10%), and magnesium stearate (1-5%). This composite structure leverages the complementary properties of each component - microcrystalline cellulose provides structural integrity and porosity, silicon dioxide prevents caking and improves flow, and magnesium stearate provides lubrication. The synergistic combination enables high drug load while maintaining dissolution performance.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure provides high-load tablet formulations of AG10 or a pharmaceutically acceptable salt thereof. In some aspects, provided herein are table formulations of AG10 or a pharmaceutically acceptable salt thereof that include at least 40% or more AG10 by weight and at least one pharmaceutical excipient selected from one or more fillers, one or more binders, one or more disintegrants, and one or more lubricants.